Erythema gyratum repens: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 51: Line 51:


==Risk Factors==
==Risk Factors==
There are no established risk factors for EGR.  
* There are no established risk factors for EGR.  


==Screening==
==Screening==
There is no screening tests for EGR but the skin rash shouldn't be missed in the the ED and patients should be referred for urgent evaluation and screening for internal malignancies.  
* There are no screening tests for EGR.
* Screening for internal malignancy should be done immediately after EGR is diagnosed.  


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
Patients with EGR usually presents with the severely pruritic rash few months prior to the diagnosis of the internal malignancy. The pruritus can be debilitating and it may persist to the time of death.  
* The majority of patients with EGR presents with severely pruritic erythematous skin lesions that appear several months prior to the malignancy diagnosis.
* If the underlying malignancy left untreated, the debilitating pruritus could persist until the patient dies.  
*Prognosis depends on the type of the underlying tumor and the probability of its treatment.  


==Diagnosis==
==Diagnosis==
===Diagnostic Study of Choice===
===Diagnostic Study of Choice===
EGR is mainly diagnosed clinically. Eosinophilia is observed in 60% of cases and immunofluorescence shows patterns of IgG, C3, and C4 at the basement membrane. 
* EGR is mainly diagnosed clinically by its characteristic skin lesions.  
 
===History and Symptoms===
===History and Symptoms===
The hallmark of EGR is skin rash  and pruritus is almost a universal symptom that can be extreme and debilitating. Patient may also complain of weight loss, anorexia, fatigue, and fever.        
* The universal symptoms of EGR are:
** Skin eruptions
** Intense pruritus  
* Other symptoms related to the associated internal malignancy are:
** Weight loss
** Anorexia
** Fatigue
** Fever        


===Physical Examination===
===Physical Examination===
Patients with EGR presents with a rash consisting of wavy erythematous concentric bands that can be figurate, gyrate, or annular. The bands are arranged in parallel rings and lined by a fine trailing edge of scale, a pattern often described as “wood grained. The rash typically involves large areas of the body but tends to spare the face, hands, and feet and it can expands as fast as a cm a day. Bullae can also form from within the areas of erythema.
* Patients with EGR presents with a rash consisting of wavy erythematous concentric bands that can be figurate, gyrate, or annular.
* The bands are arranged in parallel rings and lined by a fine trailing edge of scale, a pattern often described as “wood grained.  
* The rash typically involves large areas of the body but tends to spare the face, hands, and feet and it can expand as fast as a cm a day.  
* Bullae can also form from within the areas of erythema.


===Laboratory Findings===
===Laboratory Findings===
There are no diagnostic laboratory findings associated with EGR.
* There are no diagnostic laboratory findings associated with EGR.
 
* Eosinophilia is observed in 60% of cases
===Electrocardiogram===
There are no ECG findings associated with EGR.
 
===X-ray===
There are no x-ray findings associated with EGR.
 
===Echocardiography or Ultrasound===
There are no echocardiography/ultrasound  findings associated with EGR.
 
===CT scan===
CT findings could be seen in the associated visceral malignancy in EGR.


===MRI===
There are no MRI findings associated with EGR.


===Other Imaging Findings===
=== Imaging Findings===
* There are no imaging findings associated with EGR.
* Imaging of the chest and abdomen could show malignancy findings.


===Other Diagnostic Studies===
===Other Diagnostic Studies===
Although skin appearance is characteristic, EGR has nonspecific histopathologic features. Biopsy specimens display acanthosis, mild hyperkeratosis, focal parakeratosis, and spongiosis confined to the epidermis and superficial dermis. Mononuclear, lymphocytic, and histiocytic perivascular infiltrate in the superficial plexus can also be seen. Basement membrane deposits of IgG, C3, or C4 have been noted under direct immunofluorescence in some cases. 
* Direct immunofluorescence in some cases shows patterns of IgG, C3, and C4 at the basement membrane. 
* The histopathologic features of EGR is non-specific.  
* Biopsy specimens show the following:
** Acanthosis, mild hyperkeratosis, focal parakeratosis, and spongiosis confined to the epidermis and superficial dermis.  
** Mononuclear, lymphocytic, and histiocytic perivascular infiltrate in the superficial plexus can also be seen.  


==Treatment==
==Treatment==
Various dermatologic and immunosuppressive therapies have been used to treat EGR. Systemic steroids are frequently ineffective. Topical steroids, vitamin A, and azathioprine have also failed to relieve skin manifestations. Improvement or resolution of EGR, and its associated intense pruritus, depends on recognition and treatment of the underlying malignancy. In patients with widely metastatic disease, the response of EGR to chemotherapy is variable. In such cases, patients may not experience resolution of the rash until just before the time of death, a time of significant immunosuppression   
'''Medical Therapy'''
 
* There is no treatment for EGR; the mainstay of therapy is supportive care and treating the underlying condition.
===Medical Therapy===
* Various dermatologic and immunosuppressive therapies have been used to treat EGR.  
There is no treatment for EGR]; the mainstay of therapy is underlying malignancy.
* Systemic steroids are frequently ineffective.  
* Topical steroids, vitamin A, and azathioprine have also failed to relieve skin manifestations.
* Improvement of EGR, and its associated intense pruritus depends on recognition and treatment of the underlying malignancy.
* Chemotherapy can be used to treat the internal malignancy.  


===Surgery===
===Surgery===
Surgical intervention is not recommended for the management of EGR.
* Surgical resection of the internal tumor could be recommended as part of the management of EGR.
 
'''Prevention'''
===Primary Prevention===
* There are no primary preventive measures available for [disease name].
There are no established measures for the primary prevention of EGR.
 
===Secondary Prevention===
There are no established measures for the secondary prevention of EGR.


==References==
==References==

Revision as of 14:00, 20 June 2019

WikiDoc Resources for Erythema gyratum repens

Articles

Most recent articles on Erythema gyratum repens

Most cited articles on Erythema gyratum repens

Review articles on Erythema gyratum repens

Articles on Erythema gyratum repens in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Erythema gyratum repens

Images of Erythema gyratum repens

Photos of Erythema gyratum repens

Podcasts & MP3s on Erythema gyratum repens

Videos on Erythema gyratum repens

Evidence Based Medicine

Cochrane Collaboration on Erythema gyratum repens

Bandolier on Erythema gyratum repens

TRIP on Erythema gyratum repens

Clinical Trials

Ongoing Trials on Erythema gyratum repens at Clinical Trials.gov

Trial results on Erythema gyratum repens

Clinical Trials on Erythema gyratum repens at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Erythema gyratum repens

NICE Guidance on Erythema gyratum repens

NHS PRODIGY Guidance

FDA on Erythema gyratum repens

CDC on Erythema gyratum repens

Books

Books on Erythema gyratum repens

News

Erythema gyratum repens in the news

Be alerted to news on Erythema gyratum repens

News trends on Erythema gyratum repens

Commentary

Blogs on Erythema gyratum repens

Definitions

Definitions of Erythema gyratum repens

Patient Resources / Community

Patient resources on Erythema gyratum repens

Discussion groups on Erythema gyratum repens

Patient Handouts on Erythema gyratum repens

Directions to Hospitals Treating Erythema gyratum repens

Risk calculators and risk factors for Erythema gyratum repens

Healthcare Provider Resources

Symptoms of Erythema gyratum repens

Causes & Risk Factors for Erythema gyratum repens

Diagnostic studies for Erythema gyratum repens

Treatment of Erythema gyratum repens

Continuing Medical Education (CME)

CME Programs on Erythema gyratum repens

International

Erythema gyratum repens en Espanol

Erythema gyratum repens en Francais

Business

Erythema gyratum repens in the Marketplace

Patents on Erythema gyratum repens

Experimental / Informatics

List of terms related to Erythema gyratum repens

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Gammel's disease.


Overview

Historical Perspective

  • In 1953, the dermatologist, Dr. John A Gammel who was trained to link skin lesions to internal malignancy was the first one who described and labeled Erythema Granulatum Repens in a 55-year-old patient with poorly differentiated breast adenocarcinoma
  • Up to 1992, there were only 49 cases in the literature, 41 of which (84%) were associated with a neoplasm
  • EGR is associated with internal malignancy in 82% of cases. However, between 1990 and 2010, data was collected from the medical records of patients form dermatology department in University of Genoa and from databases as pubmed and medline, the conclusion of this literature review was that EGR is no longer considered as an obligate paraneoplastic syndrome. More than expected cases of EGR were found with no neoplasm association. Non-paraneoplastic EGR could be:
    • Idiopathic EGR
    • EGR-like eruptions (different dermatologic lesions that mimic EGR)
    • Drug-induced EGR


Classification

  • There is no established system for the classification of EGR.

Pathophysiology

  • The cause of EGR has not been identified.
  • Many theories suggest that EGR is due to immunologic mechanisms
  • The immunologic mechanism theory is evidenced by the observed immunofluorescence patterns of IgG, C3, and C4 at the basement membrane
    • Theory 1 the tumor induces antibodies that cross-react with the basement membrane of skin
    • Theory 2 the tumor produces polypeptides that bind skin antigens and render them immunogenic 
    • Theory 3 deposition of tumor antigen-antibody complexes onto the basement membrane causes the reactive dermatitis seen in EGR


Causes

The cause of erythema gyratum repens has not been identified.

Differentiating ((Page name)) from Other Diseases

  • EGR has a narrow differential diagnosis and it has to be differentiated from skin lesions with gyrate erythematous eruptions, such as:
    • Necrolytic migratory erythema (NME)
    • Erythema annulare centrifugum (EAC)
    • Erythema migrans

Epidemiology and Demographics

  • EGR is a rare dermatologic disease

Age

  • The average age of onset of EGR is in the seventh decade of life

Gender

  • The male to female ratio is 2:1

Race

  • EGR commonly affects Caucasians

Risk Factors

  • There are no established risk factors for EGR.

Screening

  • There are no screening tests for EGR.
  • Screening for internal malignancy should be done immediately after EGR is diagnosed.

Natural History, Complications, and Prognosis

  • The majority of patients with EGR presents with severely pruritic erythematous skin lesions that appear several months prior to the malignancy diagnosis.
  • If the underlying malignancy left untreated, the debilitating pruritus could persist until the patient dies.
  • Prognosis depends on the type of the underlying tumor and the probability of its treatment.

Diagnosis

Diagnostic Study of Choice

  • EGR is mainly diagnosed clinically by its characteristic skin lesions.

History and Symptoms

  • The universal symptoms of EGR are:
    • Skin eruptions
    • Intense pruritus
  • Other symptoms related to the associated internal malignancy are:
    • Weight loss
    • Anorexia
    • Fatigue
    • Fever

Physical Examination

  • Patients with EGR presents with a rash consisting of wavy erythematous concentric bands that can be figurate, gyrate, or annular.
  • The bands are arranged in parallel rings and lined by a fine trailing edge of scale, a pattern often described as “wood grained.
  • The rash typically involves large areas of the body but tends to spare the face, hands, and feet and it can expand as fast as a cm a day.
  • Bullae can also form from within the areas of erythema.

Laboratory Findings

  • There are no diagnostic laboratory findings associated with EGR.
  • Eosinophilia is observed in 60% of cases


Imaging Findings

  • There are no imaging findings associated with EGR.
  • Imaging of the chest and abdomen could show malignancy findings.

Other Diagnostic Studies

  • Direct immunofluorescence in some cases shows patterns of IgG, C3, and C4 at the basement membrane.
  • The histopathologic features of EGR is non-specific.
  • Biopsy specimens show the following:
    • Acanthosis, mild hyperkeratosis, focal parakeratosis, and spongiosis confined to the epidermis and superficial dermis.
    • Mononuclear, lymphocytic, and histiocytic perivascular infiltrate in the superficial plexus can also be seen.

Treatment

Medical Therapy

  • There is no treatment for EGR; the mainstay of therapy is supportive care and treating the underlying condition.
  • Various dermatologic and immunosuppressive therapies have been used to treat EGR.
  • Systemic steroids are frequently ineffective.
  • Topical steroids, vitamin A, and azathioprine have also failed to relieve skin manifestations.
  • Improvement of EGR, and its associated intense pruritus depends on recognition and treatment of the underlying malignancy.
  • Chemotherapy can be used to treat the internal malignancy.

Surgery

  • Surgical resection of the internal tumor could be recommended as part of the management of EGR.

Prevention

  • There are no primary preventive measures available for [disease name].

References

Template:WikiDoc Sources